Document:

Exhibit 4.4

 

Form of Subordinated Note

 

(FACE OF SECURITY)

 

[Each Global Security shall bear substantially the following legend

 

UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

 

[If the Security has original issue discount for U.S. federal income tax purposes, insert tax legend:

 

[FOR PURPOSES OF SECTIONS  1272 , 1273, and 1275 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (“THE CODE”),  THIS SECURITY IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT.  THE AMOUNT OF ORIGINAL ISSUE DISCOUNT (AS DEFINED IN SECTION 1273(A)(1) OF THE CODE AND TREASURY REGULATION SECTION 1.1273-1(A)) WITH RESPECT TO THIS SECURITY IS             , THE ISSUE DATE (AS DEFINED IN SECTION 1275(A)(2) OF THE CODE AND TREASURY REGULATION SECTION 1.1273-2(A)(2)) OF THIS SECURITY IS               , THE ISSUE PRICE (AS DEFINED IN SECTION 1273(B) OF THE CODE AND TREASURY REGULATION SECTION 1.1273-2(A)) OF THIS SECURITY IS               , AND THE YIELD TO MATURITY (AS DEFINED IN TREASURY REGULATION SECTION 1.1272-1(B)) OF THIS SECURITY IS               .] ]

 

 

PACIRA PHARMACEUTICALS, INC.
 [ Title of Security ]

 

	
No. [   ]
    	
CUSIP No.:  [   ]
    
	
 
    	
[Common Code][ISIN]:   [    ]
    
	
 
    	
[$   ]
    

 

Pacira Pharmaceuticals, Inc., a Delaware corporation (“Issuer”, which term includes any successor corporation), for value received promises to pay to [If the Security is a Global Security — CEDE & CO.][If the Security is not a Global Security —                     ] or registered assigns, the principal sum of                      on                     ,         (the “Maturity Date”) [If the Security is to bear interest prior to maturity, insert—, and to pay interest thereon from                            or from the most recent interest payment date to which interest has been paid or duly provided for, [semiannually in arrears on              and              in each year], commencing                   ,          (each, an “Interest Payment Date”) at the rate of [      % per annum], until the principal hereof is paid or made available for payment [If applicable insert—, and (to the extent that the payment of such interest shall be legally enforceable) at the rate of       % per annum on any overdue principal and on any overdue installment of interest].  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture (as defined below), be paid to the Holder in whose name this Security (or one or more predecessor Securities) is registered at the close of business on the record date for such interest, which shall be the                or                   (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date (each, an “Interest Record Date”).  Interest will be computed on the basis of [a 360-day year of twelve 30-day months].]

 

[If the Security is not to bear interest prior to maturity, insert—The principal of this Security shall not bear interest except in the case of a default in payment of principal upon acceleration, upon redemption or at maturity and, in each such case, the overdue principal of this Security shall bear interest at the rate of        % per annum (to the extent that the payment of such interest shall be legally enforceable), which shall accrue from the date of such default in payment to the date payment of such principal has been made or duly provided for.  Interest on any overdue principal shall be payable on demand.]

 

Reference is made to the further provisions set forth on the reverse of this Security contained herein, which will for all purposes have the same effect as if set forth at this place.

 

 

IN WITNESS WHEREOF, the Issuer has caused this Security to be signed manually or by facsimile by its duly authorized officer under its corporate seal.

 

 

	
 
    	
PACIRA   PHARMACEUTICALS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
Title:
    	
 
    
	
 
    	
 
    
	
Attest:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
Name:
    	
 
    	
 
    	
 
    
	
Title:
    	
 
    	
 
    	
 
    

 

This is one of the Securities of the series designated herein and referred to in the within-mentioned Indenture.

 

	
Dated:  [   ]
    	
 
    
	
 
    	
 
    
	
 
    	
                                ,   as Trustee
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Title:
    	
 
    

 

 

(REVERSE OF SECURITY)

 

PACIRA PHARMACEUTICALS, INC.

 

[ Title of Security ]

 

1.              Indenture

 

This Security is one of a duly authorized issue of debentures, notes or other evidence of indebtedness (hereinafter called the “Securities”) of the Issuer of the series hereinafter specified, which series is initially limited in aggregate principal amount to [$]                        , all of such Securities issued and to be issued under an Indenture dated as of                 ,            (the “Indenture”) between the Issuer and                                                      as trustee (the “Trustee”).  Capitalized terms herein are used as defined in the Indenture unless otherwise indicated.  The terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the Indenture.  The Securities are subject to all such terms, and Holders are referred to the Indenture and the Trust Indenture Act for a statement of all such terms.  To the extent permitted by applicable law, in the event of any inconsistency between the terms of this Security and the terms of the Indenture, the terms of the Indenture shall control.

 

This Security is one of a series of Securities designated pursuant to the Indenture [and an [Supplemental Indenture] dated           ,           , issued pursuant to Section 2.01 and Section 2.03 thereof (the “Supplement”)] as                                 .  The Securities are general unsecured obligations of the Issuer.  The Issuer may, subject to the provisions of the Indenture and applicable law, issue additional Securities of any series under the Indenture.

 

2.              Method of Payment.

 

The Issuer shall pay interest on the Securities (except defaulted interest) to the persons who are the registered Holders at the close of business on the Interest Record Date immediately preceding the Interest Payment Date notwithstanding any transfer or exchange of such Security subsequent to such Interest Record Date and prior to such Interest Payment Date. Holders must surrender Securities to the Trustee to collect principal payments. The Issuer shall pay Principal and interest in money of [the United States] that at the time of payment is legal tender for payment of public and private debts. [However, the payments of interest, and any portion of the Principal (other than interest payable at maturity or on any redemption or repayment date or the final payment of Principal) shall be made by the Paying Agent, upon receipt from the Issuer of immediately available funds by                      [a./p.m.], New York City time (or such other time as may be agreed to between the Issuer and the Paying Agent or the Issuer), directly to a Holder (by Federal funds wire transfer or otherwise) if the Holder has delivered written instructions to the Trustee 15 days prior to such payment date requesting that such payment will be so made and designating the bank account to which such payments shall be so made and in the case of payments of Principal surrenders the same to the Trustee in exchange for a Security or Securities aggregating the same principal amount as the unredeemed principal amount of the Securities surrendered.]

 

 

3.                                      Redemption.

 

[The Securities of this series may be redeemed at any time [on or after             ,             ], as a whole or in part, at the option of the Issuer, upon mailing notice of such redemption not less than 30 and not more than 60 days to the Holders of such Securities, at a redemption price equal to                       .]

 

4.              Paying Agent and Security Registrar

 

Initially, the Trustee will act as Paying Agent and Security Registrar.  The Issuer may change any Paying Agent or Security Registrar without notice to the Holders.

 

5.              Denominations; Transfer; Exchange.

 

The Securities are in registered form, without coupons, in denominations of [$1,000] and multiples of [$1,000]. A Holder shall register the transfer of or exchange Securities in accordance with the Indenture. The Issuer may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay certain transfer taxes or similar governmental charges payable in connection therewith as permitted by the Indenture. [The Issuer need not register the transfer of or exchange (a) any Securities for a period of fifteen (15) days preceding the first mailing of notice that such Securities are to be redeemed, or (b) any Securities selected, called or being called for redemption in whole or in part, except, in the case of any Security to be redeemed in part, the portion thereof not to be so redeemed.]

 

6.              Persons Deemed Owners.

 

The registered Holder of a Security shall be treated as the owner of it for all purposes.

 

7.              Unclaimed Funds.

 

If funds for the payment of principal or interest remain unclaimed for two years, the Trustee and the Paying Agent will repay the funds to the Issuer. After that, all liability of the Trustee and such Paying Agent with respect to such funds shall cease.

 

8.              Defeasance.

 

The Indenture [as amended by the Supplement] contains provisions for defeasance at any time of (a) the entire indebtedness of the Issuer on this Security and (b) certain restrictive covenants and the related Events of Default, upon compliance by the Issuer with certain conditions set forth therein, which provisions [apply] to this Security.

 

9.              Amendment; Supplement; Waiver.

 

Subject to certain exceptions, the Securities of this series, [the Supplement] and the provisions of the Indenture relating to the Securities of this series may be amended or supplemented with the written consent of the Holders of at least a majority in aggregate principal amount of the Securities of this series then outstanding, and any existing Default or Event of Default, other than the non-payment of the principal amount of or interest on the Securities of

 

5

 

this series, or compliance with certain provisions may be waived with the consent of the Holders of a majority in aggregate principal amount of all the Securities of this series, then outstanding. Without notice to or consent of any Holder, the parties thereto may amend or supplement the Indenture and the Securities to, among other things, cure any ambiguity, defect or inconsistency, provide for uncertificated Securities in addition to or in place of certificated Securities, or make any other change that does not adversely affect the rights of any Holder of a Security.

 

10.       Defaults and Remedies.

 

If an Event of Default (other than certain bankruptcy Events of Default with respect to the Issuer) occurs and is continuing, the Trustee or the Holders of at least 25% in aggregate principal amount of Securities of this series then outstanding (voting as a separate class) by notice in writing to the Issuer (and also to the Trustee if such notice is given by the Holders) may declare [the entire principal] of the Securities of this series and the interest accrued thereon, if any, to be due and payable immediately in the manner and with the effect provided in the Indenture. If a bankruptcy Event of Default with respect to the Issuer occurs and is continuing, then [the entire principal] of the Securities then outstanding and interest accrued thereon, if any, shall become due and payable immediately in the manner and with the effect provided in the Indenture.  Holders of Securities may not enforce the Indenture or the Securities except as provided in the Indenture. The Trustee is not obligated to enforce the Indenture or the Securities unless it has received indemnity satisfactory to it. The Indenture permits, subject to certain limitations therein provided, Holders of a majority in aggregate principal amount of the Securities then outstanding to direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders of Securities notice of certain continuing Defaults or Events of Default if it determines that withholding notice is in their interest.

 

11.       Subordination.

 

Reference is made to the Indenture, including, without limitation, provisions subordinating the payment of principal of and premium, if any, and interest on the Securities to the prior payment in full of all Senior Indebtedness as defined in the Indenture.  Such further provisions shall for all purposes have the same effect as though fully set forth at this place.

 

12.       Trustee Dealings with Issuer.

 

The Trustee under the Indenture, in its individual or any other capacity, may become the owner or pledgee of Securities and may otherwise deal with the Issuer as if it were not the Trustee.

 

13.       No Recourse Against Others.

 

No stockholder, director, officer, employee or incorporator, past, present or future as such, of the Issuer or any predecessor or successor corporation thereof shall have any liability for any obligation under the Securities or the Indenture or for any claim based on, in respect of or by reason of, such obligations or their creation. Each Holder of a Security by accepting a Security waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the Securities.

 

6

 

14.       Authentication.

 

This Security shall not be valid until the Trustee manually signs the certificate of authentication on this Security.

 

15.       Abbreviations and Defined Terms.

 

Customary abbreviations may be used in the name of a Holder of a Security or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).

 

16.       CUSIP Numbers.

 

Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Issuer has caused CUSIP numbers to be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the accuracy of such numbers as printed on the Securities and reliance may be placed only on the other identification numbers printed hereon.

 

17.       Governing Law.

 

The laws of the State of New York shall govern the Indenture and this Security thereof, and for all purposes this Security shall be governed by and construed in accordance with the laws of such State without regard to any principle of conflict of laws that would require or permit the application of the laws of any other jurisdiction, except as may otherwise be required by mandatory provisions of law.

 

7

 

ASSIGNMENT FORM

 

I or we assign and transfer this Security to

 

 

	
 
    
	
(Print or type name, address and zip code of assignee or transferee)
    
	
 
    
	
 
    
	
(Insert Social Security or other identifying number of assignee or   transferee)
    

 

and irrevocably appoint ________________________________________________ agent to transfer this Security on the books of the Issuer.  The agent may substitute another to act for him.

 

	
Dated:
    	
 
    	
 
    	
Signed:
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
(Signed   exactly as name appears on the other side of this Security)
    

 

	
Signature
    	
 
    	
 
    
	
Guarantee:
    	
 
    	
 
    
	
 
    	
Participant   in a recognized Signature Guarantee Medallion Program (or other signature   guarantor program reasonably acceptable to the Trustee)
    

 

8Orgenesis, Inc. - Exhibit 10.1 - Filed by newsfilecorp.com

AGREEMENT 

This Agreement (the “Agreement”) is made and entered into
effective as of April 3, 2014 (the ”Effective Date”), between Orgenesis, Inc., a
Nevada corporation, with its principal offices located at 21 Sparrow Circle,
White Plains, NY 10605, United States of America (the “COMPANY”) and Aspen
Agency Limited, a Hong Kong corporation, with a principal address at Unit 1010,
10/F Miramar Tower, 132 Nathan Road, Tsimshatsui, Kowloon, Kong Kong S.A.R. (the
”CONSULTANT”). 

WHEREAS, the Company is seeking to expand its business through
contracts with distributors and various other strategic business relationships
in Asia; and 

WHEREAS, the Company is seeking to increase market awareness of
the Company in European markets; and 

WHERAS, the Company is seeking to engage Consultant to assist
it in Investment Banking, Investor Relations, Business Development, and aligning
strategic alliances for the purposes of introducing the Company to the European
market; and 

WHEREAS, Consultant wishes to assist the Company by finding
strategic business relationships; and 

WHEREAS, Consultant has relationships which it can leverage to
assist the Company in strategic business development for its product in the
Asian markets; and 

WHEREAS, the Company wishes to retain Consultant to provide
such services for the consideration as set forth herein. 

NOW, THEREFORE, the parties agree as follows: 

1.           
 Appointment as Consultant 

Appointment. On the basis of the
representations, warranties and covenants contained in this Agreement, but
subject to the terms and conditions herein set forth, the Company is appointing
Consultant for the purpose of utilizing the Consultant’s extensive contacts to
structure and consummate strategic business relationships in the European
markets, in addition, to utilizing its expertise and the expertise of its
employees to bring awareness to the Company’s publicly traded common stock in
European markets, for a period of one year from the date of this Agreement (the
“Term”). The Term shall be automatically extended by both parties should the
Consultant be engaged in an ongoing negotiation with any targeted party as
instructed by the Company until the completion of such negotiation, or as
otherwise mutually agreed upon by the parties hereto. Consultant accepts the
appointment, agrees on the terms and conditions herein set forth and agrees to
use its best efforts during the Term to perform the services described
herein.

1.2         
 Scope of Appointment. Consultant, by virtue of this Agreement or
otherwise, is not an agent of the Company. As a Consultant for the Company under
this Agreement, Consultant is to: 

	1.2.1 	
      contact prospective offerees of the Company’s products
      and services;

	 	 
	1.2.2 	
      give such offerees information concerning the Company,
      its business and personnel as prescribed by the Company;

	 	 
	1.2.3 	
      introduce such prospective offerees to the Company which
      offerees who reside outside the United States and Canada invest in private
      placements of the Company;

	 	 
	1.2.4 	
      assist the Company in negotiations with prospective
      offerees;

	 	 
	1.2.5 	
      assist the Company in potential investment banking
      transactions in Europe; and

	 	 
	1.2.6 	
      introduce Orgenesis to the Asian
  markets.

               1.3      Nature
of Relationship. 

               1.3.1
Independent Contractor Status. Consultant shall be an independent
contractor and, except as expressly provided or authorized in this Agreement,
shall have no authority to act for or represent the Company. 

               1.3.2
Use of Other Consultants/Exclusivity. The Company shall be free to use
other Consultants for the offering of its products and services. However,
Consultant shall not, during the Term, provide services to any company which
offers products or services similar to those offered by the Company. 

               1.3.3
No Additional Compensation. Consultant shall not be entitled to any
compensation from or reimbursement of expenses by, the Company in connection
with the performance of Consultant’s duties hereunder, except as set forth
herein. 

2.            
Representations and Warranties of the Company. 

The Company represents, warrants and agrees with Consultant
that: 

               2.1
The Company is duly organized and validly existing corporation under the laws of
the State of Nevada, and has all requisite authority to own its property and
conduct its business as currently conducted. 

               2.2
The execution and delivery by the Company of this Agreement and the Option, and
the performance by the Company of its obligations hereunder, have been duly and
validly authorized by the Company. This Agreement has been duly and validly
executed and delivered by the Company and constitutes legal, valid and binding
obligations of the Company enforceable against the Company in accordance with
its terms. 

3.           
 Representations, Warranties and Covenants of the Consultant. 

Consultant represents, warrants and agrees with the Company
that Consultant has full power and authority to execute and deliver, to perform
its obligations under, and to consummate the transactions contemplated by this
Agreement. This Agreement is a valid and legally binding obligation of
Consultant, enforceable against it in accordance with its terms. Consultant is
not restricted or prohibited, contractually, by court order, agreement or
otherwise, from entering into and performing this Agreement, and the services to
be performed hereunder, and Consultant’s execution and performance of this
Agreement is not a violation or breach of any agreement between Consultant and
any other person or entity. 

Consultant will not trade in the securities of Company while in
possession of undisclosed material information regarding the Company, and will
keep all Company confidential information completely confidential and not
disclose to any party without Company’s written consent.

Consultant will comply with all applicable securities and other
laws, rules and regulations in carrying out its obligations under this
agreement.

4.            
Compensation.

As compensation for the successful completion of the
Consultant’s services as described herein, as determined by the Company acting
reasonably or as otherwise set out in this Agreement, the Company shall grant to
the Consultant the option to purchase up to 3,000,000 shares of the Company’s
common stock (“Option”) exercisable at $0.52 per share for a period of 3 years
from the date of this agreement (“Exercise Period”). After expiration of the
Exercise Period Consultant shall have no right to purchase the shares of common
stock underlying the Option. 

5.           
 Grant of Option. 

5.1         
 Grant of Option. Subject to the terms and conditions of this
Agreement, upon the execution of this Agreement, the Company will grant to the
Consultant the Option to purchase up to 3,000,000 shares of common stock (the
“Option Shares”) as listed in clause 4 upon the terms and conditions of this
Agreement. The Option will vest and be exercisable as follows: 

              
 a) 1,000,000
  Options (the “First Tranche”) will vest as at the date of execution of this
  Agreement; 

              
 b) in the event the Consultant exercises all 1,000,000 vested First
  Tranche Options during the first 12 months of this Agreement, the “Second
  Tranche” of 2,000,000 Option tranches will vest. 

Any Options that are not vested and will not vest as the
conditions listed above have not been fulfilled will terminate immediately, and
the Consultant will have no further rights with respect to the Options.

5.2         
 Exercise Price. The price to be paid by the Consultant for each
Option Share in the event of an exercise of all or any portion of the Option
shall be $0.52 (the “Exercise Price”) per Option Share.

5.3         
 Duration of Option. The Option for the First Tranche of 1,000,000
Options shall vest and become immediately exercisable, the Second Tranche shall
vest after full exercise of the First Tranche (provided the First Tranche is
exercised in full during the first 12 months of this Agreement), and all Options
shall expire on and no longer be exercisable three years from the date of this
Agreement.

5.4          
Exercise of Option.

5.4.1        Manner.
The Option may be exercised by the Consultant in whole or in part, subject to
the conditions contained herein, by the Consultant (i) paying in full the total
Exercise Price for the shares purchased and (ii) delivering, in person or by
registered mail, written notice of exercise to the Company substantially in the
form of the Option Exercise Form attached hereto as Exhibit A. As soon as
practicable after such notice and payment are received, the Company shall cause
the Consultant to be recorded on the books of the Company as the owner of the
Option Shares purchased, and the Company shall deliver to the Purchaser one or
more duly issued stock certificates evidencing such ownership. 

5.4.2        Payment.
At the time of exercise of this Option, the Consultant shall pay the Exercise
Price of the Option Shares by certified bank check or wire transfer in
immediately available funds made payable to the Company.

5.4.3        Shares
Restricted. The Consultant acknowledges that the Shares upon exercise of the
Options will be restricted securities under U.S. securities laws and will bear a
legend under Rule 144 promulgated under the Securities Act of 1933 as
advised by legal counsel to the Company. In the event that the Company files a
new registration statement after the execution of this Agreement for the
registration under the Securities Act of 1933 of other securities, the
Company will use reasonable efforts to include the Option Shares in the same
registration statement to register the Option Shares. The Company may determine
in its discretion or on the advice of a financial advisor that the addition of
the Option Shares would be detrimental to the Company’s interests, and in such
case it may defer the registration of the Option Shares to another registration
statement.

6.           
 Governing Law; Jurisdiction. This Agreement and the enforcement
thereof shall be governed by and construed under the laws of the State of
Nevada. The parties hereto consent to the non-exclusive jurisdiction of any
state or federal court and any appellate court from any appeal thereof in any
action or proceeding arising out of or relating to this Agreement, or the
transactions contemplated hereby. 

7.            
Termination. Consultant or the Company shall have the right to terminate
this Agreement by giving written notice to the other; provided, however, that
Consultant shall have 30 days to exercise any vested Options after termination.
The Company will not terminate this Agreement without a reasonable basis for
doing so.

8.           
 Notices. All notices provided for by this Agreement shall be made
in writing either (i) by actual delivery of the notice, or (ii) by the mailing
of the notice in the United States mail to the party's last known address, by
certified or registered mail, return receipt requested. The notice shall be
deemed to be received in case (i) on the date of its actual receipt by the party
entitled to notice and in case (ii) on the date of deposit in the United States
mail. 

9.           
 Severability. If any portion of this Agreement is held invalid or
inoperative, then, so far as is reasonable and possible (i) the remainder of
this Agreement shall be considered valid and operative and (ii) effect shall be
given to the intent manifested by the portion held invalid or inoperative. 

10.           Counterparts.
This Agreement may be executed in a number of identical counterparts, each of
which shall be deemed to be an original, but all of which constitute,
collectively, one and the same Agreement; but in making proof of this Agreement,
it shall not be necessary to produce or account for more than one counterpart.

11.          
Modification or Amendment. This Agreement may not be modified or amended
except by written agreement executed by the parties to this Agreement. 

12.          
Captions. The captions used in this Agreement are for convenience only
and shall not be construed in interpreting this Agreement. 

13.          
Parties. This Agreement shall be binding upon and inure solely to the
benefit of the parties to this Agreement, the controlling persons of the parties
and their respective successors, legal representatives, heirs and assigns, and
no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of by virtue of this Agreement or any
provision contained in this Agreement. 

14.          
Entire Agreement. This Agreement contains the entire understanding
between the parties and supersedes any prior understanding or written or oral
agreements between them respecting the subject matter of this Agreement. 

15.          
Arbitration. In the event that there shall be a dispute, controversy or
claim arising out of, relating to or in connection with this Agreement or
related to the subject matter hereof, the Parties agrees that such dispute shall
be submitted to binding arbitration in New York City, under the auspices of, and
pursuant to the rules of, the American Arbitration Association as then in
effect, or such other procedures as the Parties may agree to at the time, before
a tribunal of three arbitrators, one of which shall be selected by each of the
Parties to the dispute and the third of which shall be selected by the two
arbitrators so selected. Any award issued as a result of such arbitration shall
be final and binding between the Parties, and shall be enforceable by any court
having jurisdiction over the Party against whom enforcement is sought. 

16.          
Indemnification. 

               a.
Indemnification of Company by Consultant. Consultant agrees to indemnify and
hold harmless the Company and its officers, directors, employees and agents, up
to the amount of compensation received under this Agreement, against any and all
loss, liability, claims, damage and expense, including reasonable attorney fees,
arising out of or based upon Finder’s breach of this Agreement. 

               b.
Indemnification of Consultant by Company. The Company agrees to indemnify and
hold harmless Consultant, against any and all loss, liability, claims, damage
and expense, including reasonable attorney fees, arising out of or based on this
Agreement, including, but not limited to (1) a breach of this Agreement by the
Company or (2) any claims arising out of Consultant’s performance of services
under this Agreement, provided such performance was lawful, in compliance with
the Company’s instructions and made in good faith. 

IN WITNESS WHEREOF, the undersigned have executed this
Agreement on the date set opposite their respective signatures below, but
effective as provided herein. 

	Orgenesis, Inc. 	 	Aspen Agency Limited 
	 	 	 
	By: 	/s/
      Vered Caplan 	 	By: 	/s/
      Charles van Musscher 
	 	 	 	 	 
	Name: 	Vered
      Caplan 	 	Name: 	Charles van Musscher 
	 	 	 	 	 
	Title: 	CEO 	 	Title: 	Director 
	 	 	 	 	 
	Date: 	April
      3, 2014 	 	Date: 	April
      3, 2014 

EXHIBIT A 
OPTION EXERCISE FORM 

         
  This Option Exercise Form (this “Agreement”) by and between the
undersigned optionee, Aspen Agency Limited, a Hong Kong registered corporation
(the “Optionee”), and the undersigned optionor, Orgenesis, Inc. (the “Company”),
is executed and delivered pursuant to the Consulting Agreement (“Agreement”)
dated April 3, 2014 by and between the Optionee and the Company. 

      
     Subject to the foregoing, the Optionee hereby
purchases _________________shares (the “Option Shares”) of common stock of the
Company pursuant to that certain option (the “Option”) granted to the Optionee
under the Agreement. Such shares are purchased at a per share exercise price of
$0.52 per share (“Exercise Price”). 

        
   Concurrently upon the delivery of this Agreement to the
Company, the Optionee is delivering the Exercise Price multiplied by the number
of shares purchased by Optionee to the Company in accordance with and in the
manner set forth in the Agreement. Upon receipt of this notice and payment, the
Company hereby agrees to immediately (i) cause the Optionee to be recorded on
the books of the Company as the owner of the Option Shares purchased, and (ii)
deliver to the Optionee one or more duly issued stock certificates evidencing
such ownership.

           
Dated: [__________________] 

	 	Aspen Agency Limited, 
	 	Optionee 
	 	 
	 	By:
      _____________________________________________
	 	 
	 	 
	 	  
	 	Receipt Acknowledged By: 
	 	 
	 	Orgenesis, Inc. 
	 	 
	 	 
	 	By:
      _____________________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]